What is CJC-1295 studied for?

Published and ongoing research looks at sustained IGF-1 elevation in early human trials; combined effect with ghrelin-receptor agonists like Ipamorelin; body composition and recovery signaling. These are areas of study, not promised outcomes.

Is CJC-1295 FDA-approved?

CJC-1295 is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.

How is CJC-1295 typically used?

DAC and non-DAC behave very differently; they are not interchangeable IGF-1 monitoring is how response and overshoot are tracked Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.

What are the risks and unknowns with CJC-1295?

Availability varies and formulations change; not all versions are pharmacy-available Contraindicated with active malignancy Water retention, joint discomfort and carpal-tunnel-type symptoms are dose-related signals to reduce

Growth hormone secretagogues

CJC-1295

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending.

Also known as with or without DAC

A GHRH analog with extended half-life, studied to raise baseline growth-hormone and IGF-1 signaling.

What it is

CJC-1295 is a modified GHRH analog. The DAC (drug affinity complex) version binds albumin and lasts for days, raising baseline GH; the version without DAC — often called modified GRF (1-29) — acts in a short pulse closer to natural physiology.

What it's studied for

Sustained IGF-1 elevation in early human trials
Combined effect with ghrelin-receptor agonists like Ipamorelin
Body composition and recovery signaling

How it's used in practice

DAC and non-DAC behave very differently; they are not interchangeable
IGF-1 monitoring is how response and overshoot are tracked

What you should know before asking about it

Availability varies and formulations change; not all versions are pharmacy-available
Contraindicated with active malignancy
Water retention, joint discomfort and carpal-tunnel-type symptoms are dose-related signals to reduce

Frequently asked questions.

What is CJC-1295?: CJC-1295 is a modified GHRH analog. The DAC (drug affinity complex) version binds albumin and lasts for days, raising baseline GH; the version without DAC — often called modified GRF (1-29) — acts in a short pulse closer to natural physiology.
What is CJC-1295 studied for?: Published and ongoing research looks at sustained IGF-1 elevation in early human trials; combined effect with ghrelin-receptor agonists like Ipamorelin; body composition and recovery signaling. These are areas of study, not promised outcomes.
Is CJC-1295 FDA-approved?: CJC-1295 is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
How is CJC-1295 typically used?: DAC and non-DAC behave very differently; they are not interchangeable IGF-1 monitoring is how response and overshoot are tracked Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
What are the risks and unknowns with CJC-1295?: Availability varies and formulations change; not all versions are pharmacy-available Contraindicated with active malignancy Water retention, joint discomfort and carpal-tunnel-type symptoms are dose-related signals to reduce

Sources

1.Published literature on CJC-1295 with or without DAC— PubMed, U.S. National Library of Medicine
2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
4.Test directory and patient service center locator— Quest Diagnostics

About this page

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.

This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.

Begin your intake Peptide therapy overview